Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims
By Ivan Moreno · February 8, 2022, 6:05 PM EST
Biogen was hit with a proposed class action Monday from investors whose shares plummeted after a controversial new Alzheimer's drug failed to deliver the financial gains they expected....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login